Search results
Down -6.19% in 4 Weeks, Here's Why ANI (ANIP) Looks Ripe for a Turnaround
Zacks via Yahoo Finance· 6 days agoANI (ANIP) has become technically an oversold stock now, which implies exhaustion of the heavy...
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) COO Sells $794,567.55 in Stock
ETF DAILY NEWS· 4 days agoANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Get Free Report) COO Muthusamy Shanmugam sold 12,855 shares of the business’s stock in a transaction on Monday, May 20th. The shares ...
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of ANI...
FOX 4 Kansas City· 6 days agoPurcell & Lefkowitz LLP announces that it is investigating ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) on behalf of the company's shareholders. The investigation seeks to determine ...
Ani Pharmaceuticals exec sells over $123k in company stock By Investing.com
Investing.com· 4 days agoANI Pharmaceuticals, Inc. (NASDAQ:ANIP) has reported a significant stock transaction by one of its...
BeiGene's (BGNE) Shares Surge 32% in a Month: Here's Why
Zacks· 7 days agoFree Report) is a next-gen oncology company focusing on discovering and developing innovative and...
Roche Cancer Drug Gets Breakthrough Therapy Designation - Ligand Pharmaceuticals (NASDAQ:LGND), ANI...
Benzinga· 4 days agoRoche (OTC: RHHBY) obtained a Breakthrough Therapy Designation for its investigational oral therapy...
Has Acrivon Therapeutics, Inc. (ACRV) Outpaced Other Medical Stocks This Year?
Zacks· 7 days agoInvestors interested in Medical stocks should always be looking to find the best-performing companies in the group. Acrivon Therapeutics, Inc. (ACRV Quick QuoteACRV - Free Report) is a stock ...
Here's Why Merck (MRK) Stock Has Outperformed Industry YTD
Zacks via Yahoo Finance· 6 days agoQuote Some better-ranked stocks from the drug/biotech industry are Ligand Pharmaceuticals LGND and...
Exelixis (EXEL) Settles Cabometyx Patent Litigation With Cipla
Zacks via Yahoo Finance· 5 days agoExelixis (EXEL) resolves two patent litigations and grants Cipla a license to market generic...
AstraZeneca (AZN) Plans to Generate $80B in Revenues by 2030
Zacks via Yahoo Finance· 5 days agoIn the past 90 days, the Zacks Consensus Estimate for Ligand’s 2024 earnings per share has increased...